Simon Bedford

USPTO Granted Patents = 13 (Patent Applications = 4)

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 8)

Average Co-Inventor Count = 5.6

ph-index = 3

Forward Citations = 14(Granted Patents)

Location History:

Winnersh, GB (2013 - 2020)
Harlow, GB (2017 - 2020)
Great Abington, GB (2020 - 2021)

Company Filing History:

Les Laboratoires Servier

patents

where one patent can have more than one assignee

Years Active: 2013-2021

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11028097 - Thienopyrimidine compounds (2021-06-08),

2. 10696652 - Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity (2020-06-30),

3. 10662173 - Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them (2020-05-26),

4. 10556911 - Thienopyrimidine compounds (2020-02-11),

5. 9920066 - Thienopyrimidine compounds (2018-03-20),

6. 9765056 - Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them (2017-09-19),

7. 9675594 - Arylpyrrolopyridine derived compounds as LRRK2 inhibitors (2017-06-13),

8. 9610290 - Thienopyrimidine compounds (2017-04-04),

9. 9604975 - Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity (2017-03-28),

10. 9499542 - Arylpyrrolopyridine derived compounds as LRRK2 inhibitors (2016-11-22),

11. 9120807 - Thienopyrimidine compounds (2015-09-01),

12. 8916591 - Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity (2014-12-23),

13. 8354415 - Thienopyrimidine compounds and compositions (2013-01-15),

Title: The Innovative Contributions of Simon Bedford

Introduction

Simon Bedford is a notable inventor based in Winnersh, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds. With a total of 13 patents to his name, Bedford's work has had a considerable impact on medical research and treatment options.

Latest Patents

Among his latest patents are the Thienopyrimidine compounds, which are A receptor antagonists. These compounds are characterized by a complex formula that includes various substituents, showcasing Bedford's expertise in medicinal chemistry. Another significant patent involves Indolyl-pyridone derivatives that exhibit checkpoint kinase 1 inhibitory activity. This innovation presents a method for treating mammals suffering from cancer by inhibiting protein kinase activity, highlighting the potential therapeutic applications of his work.

Career Highlights

Throughout his career, Simon Bedford has worked with reputable companies such as Vernalis (R&D) Limited and H. Lundbeck A/S. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in the pharmaceutical industry.

Collaborations

Bedford has collaborated with esteemed colleagues, including Allan Michael Jordan and Klenke Burkhard. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Simon Bedford's contributions to the field of pharmaceuticals through his patents and collaborations demonstrate his commitment to advancing medical science. His innovative work continues to pave the way for new treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.